Jason McCarthy

Jason McCarthy is a Senior Managing Director and Head of Biotechnology Research at Maxim Group, LLC.5 He holds a Ph.D. and specializes in equity research covering the biotechnology industry.7 McCarthy joined Maxim Group in July 2014.7

As an equity analyst, McCarthy covers 177 stocks in the Healthcare sector with a focus on biotechnology.3 His stock recommendations have a 28% success rate and an average return of -13.70% per rating.3 McCarthy has made 414 price targets and ratings on 66 stocks throughout his career.1

Some key points about Jason McCarthy's work:

1. He is currently employed at Maxim Group, a full-service investment bank, securities, and wealth management firm based in mid-town Manhattan.4

2. McCarthy's average stock price target met ratio is 33.82%, with a potential upside of 54.13% achieved within 179 days.1

3. His most recent stock forecast was for Capricor Therapeutics (CAPR) on September 17, 2024.1

4. McCarthy's best-performing recommendation was for ANVS (Annovis Bio) on May 13, 2021, with a price target of $45 fulfilled within 8 days, resulting in a 93.3% profit.1

5. He participates in industry events, such as hosting fireside chats with CEOs of biotechnology companies at Maxim Group's Virtual Healthcare Summit.2

Jason McCarthy is based in Sea Cliff, NY, and can be found on LinkedIn under the username jason-mccarthy-phd-90a1a665.6